Healthcare

Delivering solutions in M&A, Capital Raising, and Restructuring

Healthcare Investment Banking Group

Finding financial solutions across every sector of the healthcare ecosystem.

A full-service healthcare investment banking practice offering a best-in-class combination of deep sector knowledge, strong industry relationships, and broad product expertise.

Stifel’s Global Healthcare Investment Banking Group is comprised of 47 professionals covering all segments of the healthcare industry. The team, located in New York, San Francisco, London, Toronto, and Montreal, has substantial experience in assisting companies with all types of financing and M&A assignments. The Global Healthcare Group is dedicated to building long-term relationships with its clients through senior level attention. Since the formation of the Global Healthcare Group in Q4 2010, the team have helped raise over $79.1 billion for over 225 healthcare companies in over 440 transactions. Over the same period, members of the Global Healthcare Group have advised on over 105 announced M&A transactions, including over 30 cross-border assignments.

Our team provides clients with strategic advisory and capital-raising services designed to support growth companies and their investors during all stages of their development. We offer equity and debt capital markets services, including book running leading IPOs, follow-ons, and convertible note issuances. The Global Healthcare Group is supported by M&A advisory with extensive cross-border expertise, access to private capital markets through SPACs and 144A solutions, as well as activism defense and restructuring.

Read Our Latest Thoughts on Investment Banking in the Healthcare Sector

Learn More

Areas of Expertise

Biopharma

The biopharma sector is advancing at an unprecedented pace, driven by innovation and growth from small to large companies across all stages of development and therapeutic areas. Stifel’s Biopharma team is uniquely positioned to serve the needs of our clients in all types of financing and M&A assignments via our deep understanding of the biopharma landscape, and our extensive relationships and transaction experience.

Healthcare Services

The healthcare services landscape is constantly shifting, driven by changes in regulations, reimbursement, and advancements in technology. Stifel’s Healthcare Services Team works to stay abreast of these changes and is ideally positioned to serve the needs of our clients in all types of financing and M&A assignments via relationships, recent mandates, and years of thought leadership across a broad range of healthcare sub-sectors including Alternate Site, Behavioral Health, Payor Services, Pharma Services, and Physician Groups.

HealthTech

Technologies are rapidly advancing the automation of workflows across the healthcare ecosystem, the development and efficacy of treatments, and the way in which care is provided in-person and remotely. Stifel’s Healthcare Technology team brings a wealth of M&A and financing experience advising companies delivering software, digital health, data-driven, and technology-enabled solutions to providers, payors, pharmaceutical companies, and patients.

Medtech

The Medtech sector is advancing at an unprecedented pace, driven by innovation and growth from small to large companies across all Medtech subsectors. Stifel’s Medtech team is uniquely positioned to serve the needs of our clients in all types of financing and M&A assignments via our deep understanding of the Medtech landscape, and our extensive relationships and transaction experience.

Tools & Diagnostics

The life science tools & diagnostics sector is transforming at amazing speeds. Enabled by a broad array of new technologies, our ability to better understand all facets of the human genome has improved exponentially; all the while being done at greater efficiency and dramatically reduced costs. This widening knowledge set is enabling faster and more productive drug discovery, disease diagnosis and AI-enabled prognostic clinical capabilities. Stifel’s Life Science Tools & Diagnostics team is uniquely positioned to serve the needs of our clients in all types of financing and M&A assignments via our broad domain expertise, deep understanding of the competitive landscape, and our extensive relationships and transaction experience.

Notable Transactions

$ 175,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Mar 2025

$ 202,000,000

Joint Bookrunning Manager

Initial Public Offering

Medtech

Mar 2025

$ 219,200,000

Joint Bookrunner

Initial Public Offering

Biopharma

Feb 2025

$ 150,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Feb 2025

Advisor to Buyer

Mergers & Acquisitions

Healthcare

Feb 2025

$ 75,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Jan 2025

Advisor to Pieris

Mergers & Acquisitions

HealthTech

Dec 2024

$ 50,000,000

Joint Bookrunner

Registered Direct

Biopharma

Dec 2024

$ 257,600,000

Joint Bookrunner

Follow-on Offering

Biopharma

Dec 2024

Advisor to Seller

Mergers & Acquisitions

HealthTech

Dec 2024

$ 402,500,000

Joint Bookrunner

Follow-on Offering

Biopharma

Dec 2024

$ 60,000,000

Joint Bookrunner & Joint Placement Agent

Registered Direct & PIPE

Biopharma

Nov 2024

Advisor to Buyer

Mergers & Acquisitions

Biopharma

Oct 2024

Sole Financial Advisor

Mergers & Acquisitions

Healthcare Services

Oct 2024

$ 575,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Sep 2024

$ 362,250,000

Joint Bookrunner

Initial Public Offering

Biopharma

Sep 2024

$ 187,680,000

Joint Bookrunner

Initial Public Offering

Biopharma

Sep 2024

$ 258,750,000

Joint Bookrunning Manager

Follow-on Offering

Biopharma

Sep 2024

$ 200,536,320

Joint Placement Agent

PIPE

Biopharma

Sep 2024

$ 200,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Sep 2024

$ 258,750,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Aug 2024

$ 130,000,000

Joint Bookrunner

Registered Direct

Biopharma

Aug 2024

Advisor to Seller

Mergers & Acquisitions

Healthcare, Biopharma

Aug 2024

$ 100,000,000

Lead Financial Advisor

Convertible Notes & Senior Secured Term Loan

Medtech

Aug 2024

$ 33,900,000

Sole Bookrunner

Follow-on Offering

Biopharma

Aug 2024

$ 128,000,000

Financial Advisor

SPAC Merger

Medtech

Jul 2024

Advisor to Seller

Mergers & Acquisitions

Healthcare

Jul 2024

$ 310,000,000

Advisor to Seller

Mergers & Acquisitions

Medtech, Healthcare

Jul 2024

Advisor to Seller

Mergers & Acquisitions

Biopharma

Jul 2024

Advisor to Buyer

Mergers & Acquisitions

HealthTech

Jul 2024

€ 52,500,000

Exclusive Debt Advisor

Secured Credit Facility

Healthcare

Jun 2024

$ 174,400,000

Joint Bookrunner

Initial Public Offering

Biopharma

Jun 2024

$ 60,000,000

Joint Bookrunner

Registered Direct

Biopharma

May 2024

$ 374,325,000

Joint Bookrunner

Follow-on Offering

Biopharma

May 2024

$ 75,000,000

Sole Bookrunner

Registered Direct

Biopharma

May 2024

$ 94,300,000

Advisor to Sientra

Aggregate Indebtedness

Medtech

Apr 2024

$ 121,600,000

Advisor to Seller

Has Sold Assets to

Medtech

Apr 2024

$ 280,000,000

Joint Placement Agent

PIPE

Biopharma

Apr 2024

$ 201,250,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Apr 2024

$ 110,000,000

Joint Bookrunner

Initial Public Offering

Biopharma

Apr 2024

Advisor to Seller

Mergers & Acquisitions

Biopharma

Apr 2024

C$ 23,011,788

Joint Bookrunner

Follow-on Offering

Healthcare & Special Situations

Mar 2024

Financial Advisor

Mergers & Acquisitions

Biopharma

Mar 2024

$ 240,100,310

Joint Bookrunner

Registered Direct

Biopharma

Mar 2024

$ 150,000,000

Joint Bookrunner

Registered Direct

Biopharma

Mar 2024

$ 180,000,000

Joint Placement Agent

PIPE

Biopharma

Mar 2024

$ 482,999,902

Joint Bookrunner

Follow-on Offering

Biopharma

Mar 2024

$ 140,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Mar 2024

Advisor to Seller

Mergers & Acquisitions

Healthcare Services

Mar 2024

£ 31,000,000

Joint Bookrunner, Joint Corporate Broker, NOMAD

Follow-on Offering

Healthcare

Mar 2024

$ 632,540,250

Joint Bookrunner

Follow-on Offering

Biopharma

Feb 2024

$ 34,400,000

Advisor to Buyer

Mergers & Acquisitions

HealthTech

Feb 2024

C$ 6,000,000

Follow-on Offering

Biopharma

Feb 2024

$ 160,125,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Feb 2024

$ 345,144,000

Joint Bookrunner

Follow-on Offering

Biopharma

Jan 2024

$ 230,000,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Dec 2023

$ 20,300,000

Left Bookrunner

Registered Direct

HealthTech

Dec 2023

$ 180,000,000

Joint Placement Agent

PIPE

Biopharma

Dec 2023

$ 100,000,000

Advisor to Buyer

Mergers & Acquisitions

Biopharma

Dec 2023

$ 300,000,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Nov 2023

Advisor to Seller

Mergers & Acquisitions

Biopharma

Nov 2023

$ 245,000,000+

Advisor to Licensee

In-Licensing

Biopharma

Nov 2023

Advisor to Seller

Mergers & Acquisitions

HealthTech

Nov 2023

$ 111,536,216

Joint Bookrunner

Initial Public Offering

Biopharma

Nov 2023

$ 150,150,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Oct 2023

$ 517,500,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Oct 2023

€ 154,430,010

Advisor to Seller

Mergers & Acquisitions

Medtech

Oct 2023

$ 100,000,000

Joint Bookrunner

Registered Direct

Biopharma

Oct 2023

$ 90,833,010

Advisor to Buyer

Mergers & Acquisitions

Biopharma

Oct 2023

Advisor to Seller

Mergers & Acquisitions

Healthcare

Sep 2023

$ 115,000,000

Joint Bookrunner

Confidentially marketed Follow-on Offering

Biopharma

Sep 2023

$ 250,070,000

Joint Bookrunner

Initial Public Offering

Biopharma

Sep 2023

$ 130,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Jul 2023

$ 345,057,500

Joint Bookrunner

Initial Public Offering

Biopharma

Jul 2023

£ 10,000,000

Joint Bookrunner

Equity Placing

Healthcare

Jul 2023

$ 120,000,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Jun 2023

$ 137,200,000

Joint Bookrunner

Follow-on Offering

Biopharma

Jun 2023

$ 200,000,000

Investment Banker for Tricida

Chapter 11 Restructuring

Biopharma

Jun 2023

$ 460,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Mar 2023

$ 220,800,000

Joint Bookrunner

Initial Public Offering

Biopharma

Feb 2023

$ 20,300,000

Sole Placement Agent and Nomad

PIPE

Healthcare

Feb 2023

$ 100,000,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Feb 2023

$ 227,843,965

Joint Bookrunner

Follow-on Offering

Biopharma

Jan 2023

Advisor to Seller

Mergers & Acquisitions

Healthcare

Dec 2022

$ 120,000,000

Left Bookrunner

Convertible Notes

Medtech

Dec 2022

$ 115,799,748

Joint Bookrunner & Joint Placement Agent

Registered Direct & PIPE

Biopharma

Dec 2022

$ 65,010,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Dec 2022

Advisor to Seller

Mergers & Acquisitions

Maritime Services, Healthcare Services

Dec 2022

$ 300,375,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Dec 2022

$ 64,000,000

Advisor to Seller

Mergers & Acquisitions

Tools & Diagnostics

Nov 2022

$ 850,000,000

Financial and Capital Markets Advisor

Mergers & Acquisitions

Biopharma

Nov 2022

$ 115,000,000

Joint Bookrunner

Follow-on Offering

Medtech

Oct 2022

£ 64,000,000

Sole Bookrunner, Sole Placement Agent, Sole Broker and Nomad

Convertible Bond & Follow-on Offering

Healthcare Services

Oct 2022

$ 58,079,577

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Sep 2022

$ 124,800,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Sep 2022

$ 260,000,000

Advisor to Seller

Mergers & Acquisitions

Healthcare Services

Aug 2022

$ 84,249,986

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Aug 2022

$ 143,893,750

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Aug 2022

$ 862,500,000

Lead Manager

Follow-on Offering

Biopharma

Aug 2022

$ 104,500,000

Sole Placement Agent

Senior Secured Term Loan

Medtech

Jul 2022

$ 55,300,000

Sole Bookrunner

Exchange of Convertible Notes

Medtech

Jul 2022

$ 1,200,000,000

Advisor to Seller

Mergers & Acquisitions

Medtech

Jul 2022

$ 250,000,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

HealthTech

Jun 2022

C$ 34,511,565

Joint Bookrunner

Follow-on Offering

HealthTech

May 2022

£ 34,261,864

Joint Bookrunner

Follow-on Offering

Biopharma

May 2022

$ 108,000,000

Joint Bookrunner

Initial Public Offering

Biopharma

May 2022

Advisor to Seller

Mergers & Acquisitions

Healthcare Services

May 2022

$ 200,000,000

Joint Bookrunner

Initial Public Offering

Biopharma

Apr 2022

$ 230,000,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Apr 2022

€ 15,000,000

Joint Global Coordinator and Joint Bookrunner

Follow-on Offering

Healthcare

Apr 2022

$ 30,000,000

Sole Financial Advisor and Sole Placement Agent

Convertible Bond and Equity Placing

Medtech

Mar 2022

$ 230,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Mar 2022

$ 75,000,000

Left Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Mar 2022

$ 40,000,000

Financial Advisor

Registered Direct

HealthTech

Mar 2022

$ 2,350,000,000

Joint Bookrunner

Senior Notes

HealthTech

Feb 2022

$ 100,000,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Jan 2022

$ 98,000,000

Joint Bookrunner

Initial Public Offering

Biopharma

Jan 2022

Advisor to Seller

Mergers & Acquisitions

Healthcare Services

Dec 2021

$ 52,325,000

Joint Bookrunner

Follow-on Offering

Biopharma

Dec 2021

C$ 65,000,000

Co-Lead Manager

Convertible Notes

HealthTech

Nov 2021

$ 172,500,000

Left Bookrunner

SPAC IPO

Biopharma

Nov 2021

$ 80,500,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Nov 2021

$ 43,000,000

Lead Placement Agent

Private Placement

Biopharma

Nov 2021

$ 100,800,000

Joint Bookrunner

Follow-on Offering

Tools & Diagnostics

Nov 2021

$ 158,000,000

Capital Markets Advisor

Mergers & Acquisitions

HealthTech

Nov 2021

Advisor to Seller

Mergers & Acquisitions

Healthcare Services

Nov 2021

$ 230,000,000

Joint Bookrunner

Initial Public Offering

Healthcare Services

Nov 2021

$ 93,600,000

Joint Bookrunner

Initial Public Offering

Medtech

Oct 2021

$ 150,750,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Oct 2021

C$ 7,004,400

Joint Bookrunner

Follow-on Offering

Healthcare & Special Situations

Oct 2021

$ 74,865,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Oct 2021

$ 345,000,000

Joint Bookrunner

Follow-on Offering

Medtech

Oct 2021

$ 70,900,000

Advisor to Buyer

Mergers & Acquisitions

Medtech

Oct 2021

Advisor to Seller

Mergers & Acquisitions

Medtech

Oct 2021

$ 13,200,000

Joint Bookrunner

Follow-on Offering

Healthcare Services

Sep 2021

Advisor to Buyer

Mergers & Acquisitions

Medtech

Sep 2021

$ 1,000,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Sep 2021

$ 651,000,000

Capital Markets Advisor

SPAC Merger

Tools & Diagnostics

Sep 2021

Advisor to Buyer

Mergers & Acquisitions

Biopharma

Aug 2021

$ 212,000,000

Capital Markets Advisor

SPAC Merger & PIPE

Biopharma

Aug 2021

$ 355,810,000

Joint Bookrunner

Initial Public Offering

Biopharma

Aug 2021

$ 84,333,337

Joint Bookrunner

Initial Public Offering

Biopharma

Jul 2021

$ 230,000,000

Joint Bookrunner

Initial Public Offering

Tools & Diagnostics

Jul 2021

Advisor to Seller

Mergers & Acquisitions

Biopharma

Jul 2021

£ 17,000,000

Sole Global Coordinator, Joint Bookrunner & Nomad

Initial Public Offering

HealthTech

Jul 2021

$ 174,560,000

Joint Bookrunner

Initial Public Offering

Biopharma

Jul 2021

$ 180,132,080

Joint Bookrunner

Initial Public Offering

Tools & Diagnostics

Jul 2021

$ 62,675,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Jul 2021

$ 100,190,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Jul 2021

$ 350,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Jul 2021

$ 97,807,500

Joint Bookrunner

Initial Public Offering (U.S. Nasdaq)

Medtech

Jul 2021

$ 181,500,000

Advisor to Seller

Mergers & Acquisitions

Biopharma

Jul 2021

$ 160,000,000

Joint Bookrunner

Initial Public Offering

Biopharma

Jun 2021

$ 160,000,000

Joint Bookrunner

Initial Public Offering

Biopharma

Jun 2021

$ 80,000,000

Left Bookrunner

Follow-on Offering

Entertainment

Jun 2021

Advisor to Seller

Mergers & Acquisitions

Healthcare Services

Jun 2021

$ 366,000,000

Co-Manager

Follow-on Offering

Medtech

Apr 2021

$ 98,325,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Apr 2021

$ 100,912,500

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Apr 2021

$ 287,500,000

Joint Bookrunner

Follow-on Offering

Biopharma

Apr 2021

$ 646,875,000

Joint Bookrunner

Follow-on Offering

Tools & Diagnostics

Apr 2021

$ 550,000,000

Joint Bookrunner

Convertible Senior Notes

Biopharma

Apr 2021

$ 103,500,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Mar 2021

$ 50,652,000

Left Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Mar 2021

$ 30,000,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Mar 2021

$ 48,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Mar 2021

$ 56,000,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Mar 2021

$ 55,000,000

Joint Placement Agent

PIPE

Biopharma

Mar 2021

$ 218,500,000

Joint Bookrunner

Initial Public Offering

Biopharma

Mar 2021

$ 115,000,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

HealthTech

Mar 2021

$ 160,425,000

Joint Bookrunner

Follow-on Offering

Biopharma

Mar 2021

$ 138,250,000

Sole Bookrunner

Convertible Notes

Medtech

Mar 2021

$ 90,000,000

Advisor to Squadron

Has Invested in

Medtech

Mar 2021

$ 222,250,000

Joint Bookrunner

Follow-on Offering

HealthTech

Feb 2021

$ 60,000,000

Joint Bookrunner

Follow-on Offering

HealthTech

Feb 2021

$ 2,200,000,000

Co-Manager

Senior Notes

Healthcare Services

Feb 2021

$ 150,000,000

Joint Bookrunner

Follow-on Offering

HealthTech

Feb 2021

$ 42,000,000

Sole Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Feb 2021

$ 117,000,000

Joint Bookrunner

Initial Public Offering

Biopharma

Feb 2021

$ 264,500,000

Joint Bookrunner

Initial Public Offering

Biopharma

Feb 2021

$ 203,439,942

Joint Bookrunner

Initial Public Offering

Biopharma

Feb 2021

Capital Markets Advisor

SPAC Merger & PIPE

Biopharma

Feb 2021

£ 40,000,000

Sole Placement Agent

PIPE

Biopharma

Feb 2021

$ 74,500,000

Left Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Feb 2021

$ 70,000,000

Joint Placement Agent

Private Placement

HealthTech

Feb 2021

$ 129,375,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Jan 2021

$ 168,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Jan 2021

$ 103,500,000

Joint Bookrunner

Follow-on Offering

Biopharma

Jan 2021

$ 264,000,000

Joint Bookrunner

Follow-on Offering

Healthcare Services

Jan 2021

$ 555,450,000

Joint Bookrunner

Initial Public Offering

Biopharma

Dec 2020

$ 149,500,000

Joint Bookrunner

Initial Public Offering

Tools & Diagnostics

Dec 2020

$ 200,000,000

Joint Bookrunner

Follow-on Offering

Biopharma

Dec 2020

$ 345,080,500

Joint Bookrunner

Follow-on Offering

Biopharma

Dec 2020

$ 312,225,000

Joint Bookrunner

Follow-on Offering

Tools & Diagnostics

Dec 2020

$ 750,000,000

Joint Bookrunner

Follow-on Offering

Tools & Diagnostics

Dec 2020

$ 277,725,000

Joint Bookrunner

Initial Public Offering

Biopharma

Dec 2020

$ 1,863,000,000

Joint Bookrunner

Initial Public Offering

Tools & Diagnostics

Nov 2020

$ 81,176,464

Joint Bookrunner

Initial Public Offering

Biopharma

Nov 2020

$ 345,000,000

Lead Manager

Initial Public Offering

Medtech

Oct 2020

$ 104,796,260

Left Bookrunner

Initial Public Offering

Medtech

Oct 2020

$ 1,898,938,296

Joint Financial Advisor

Mergers & Acquisitions

Biopharma

Oct 2020

$ 2,128,500,000

Lead Manager

Initial Public Offering

Medtech

Oct 2020

$ 200,000,000

Joint Bookrunner

Convertible Notes

Biopharma

Sep 2020

$ 277,761,104

Joint Bookrunner

Initial Public Offering

Biopharma

Sep 2020

$ 267,696,966

Joint Bookrunner

Initial Public Offering

Biopharma

Sep 2020

$ 963,470,000

Joint Bookrunner

Follow-on Offering

Biopharma

Aug 2020

$ 140,000,000

Advisor to Seller

Mergers & Acquisitions

Biopharma

Aug 2020

$ 135,000,000

Advisor to Buyer

Mergers & Acquisitions

Biopharma

Jul 2020

$ 445,000,000

Financial Advisor

PIPE

Biopharma

Jul 2020

$ 209,000,000

Joint Bookrunner

Initial Public Offering

Biopharma

Jul 2020

$ 80,000,000

Lead Placement Agent

PIPE

Biopharma

Jul 2020

$ 120,000,000

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Jul 2020

$ 39,054,798

Advisor to Buyer

Mergers & Acquisitions

Medtech

Apr 2020

$ 79,347,051

Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Mar 2020

$ 125,000,000

Financial Advisor

Strategic Financing Agreement

Biopharma

Feb 2019

Advisor to Seller

Mergers & Acquisitions

Biopharma

Sep 2018

Paris

Hetal Vora

Director

Steven Zhou

Director

San Francisco